More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced
United States United Kingdom Catalina Loveman Peter Langmuir Ponatinib Iclusig Tafasitamab Lenalidomide
Source: finanznachrichten.de